Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.57 - $0.99 $62,939 - $109,315
-110,420 Reduced 17.89%
506,900 $420,000
Q1 2023

May 15, 2023

SELL
$0.51 - $0.78 $122,145 - $186,810
-239,500 Reduced 27.95%
617,320 $370,000
Q4 2022

Feb 14, 2023

SELL
$0.47 - $17.22 $153,643 - $5.63 Million
-326,900 Reduced 27.62%
856,820 $471,000
Q3 2022

Nov 14, 2022

SELL
$0.74 - $15.01 $148,444 - $3.01 Million
-200,600 Reduced 14.49%
1,183,720 $829,000
Q2 2022

Aug 15, 2022

BUY
$0.71 - $2.43 $667,613 - $2.28 Million
940,300 Added 211.77%
1,384,320 $1.36 Million
Q1 2022

May 16, 2022

BUY
$2.31 - $5.13 $988,726 - $2.2 Million
428,020 Added 2675.13%
444,020 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$4.45 - $8.09 $71,200 - $129,440
16,000 New
16,000 $76,000
Q4 2020

Feb 16, 2021

SELL
$1.08 - $8.2 $22,183 - $168,427
-20,540 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$0.95 - $1.42 $6,133 - $9,167
6,456 Added 45.84%
20,540 $24,000
Q2 2020

Aug 14, 2020

SELL
$0.63 - $1.7 $2,898 - $7,820
-4,600 Reduced 24.62%
14,084 $17,000
Q1 2020

May 15, 2020

SELL
$0.67 - $1.85 $335 - $925
-500 Reduced 2.61%
18,684 $13,000
Q4 2019

Feb 14, 2020

SELL
$1.36 - $2.44 $136 - $244
-100 Reduced 0.52%
19,184 $33,000
Q3 2019

Nov 14, 2019

SELL
$1.74 - $2.83 $452 - $735
-260 Reduced 1.33%
19,284 $43,000
Q2 2019

Aug 14, 2019

SELL
$1.36 - $2.35 $6,256 - $10,810
-4,600 Reduced 19.05%
19,544 $36,000
Q1 2019

May 15, 2019

SELL
$0.78 - $2.01 $16,426 - $42,330
-21,060 Reduced 46.59%
24,144 $48,000
Q4 2018

Feb 14, 2019

SELL
$0.62 - $2.25 $4,229 - $15,349
-6,822 Reduced 13.11%
45,204 $31,000
Q3 2018

Nov 14, 2018

SELL
$1.38 - $1.94 $18,906 - $26,578
-13,700 Reduced 20.84%
52,026 $93,000
Q2 2018

Aug 14, 2018

BUY
$1.73 - $3.35 $113,705 - $220,182
65,726 New
65,726 $114,000

About CURIS INC


  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $393M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.